We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

232 hedge funds and large institutions have $4.15B invested in Loxo Oncology, Inc in 2018 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 77 increasing their positions, 85 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more call options, than puts

Call options by funds: $21.9M | Put options by funds: $12.3M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

16% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 31

2% more funds holding

Funds holding: 228232 (+4)

9% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 85

19% less capital invested

Capital invested by funds: $5.13B → $4.15B (-$971M)

Holders
232
Holders Change
+4
Holders Change %
+1.75%
% of All Funds
5.17%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.16%
New
36
Increased
77
Reduced
85
Closed
31
Calls
$21.9M
Puts
$12.3M
Net Calls
+$9.55M
Net Calls Change
-$5.66M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$391M +$18.2M +119,955 +4%
BlackRock
2
BlackRock
New York
$319M +$1.45M +9,540 +0.4%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$296M -$16.2M -106,509 -5%
AC
4
Aisling Capital
New York
$286M
Fidelity Investments
5
Fidelity Investments
Massachusetts
$280M +$13.2M +86,980 +5%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$251M -$2.92M -19,224 -1%
Sands Capital Management
7
Sands Capital Management
Virginia
$241M -$18.6M -122,363 -7%
O
8
OppenheimerFunds
New York
$142M -$497K -3,275 -0.3%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$139M +$72.3M +476,119 +93%
State Street
10
State Street
Massachusetts
$125M -$6.08M -40,037 -4%
Fidelity International
11
Fidelity International
Bermuda
$77.6M +$10.3M +67,737 +14%
AllianceBernstein
12
AllianceBernstein
Tennessee
$71.3M -$9.93M -65,445 -11%
Norges Bank
13
Norges Bank
Norway
$60.8M +$2.46M +16,225 +4%
EAM
14
Eagle Asset Management
Florida
$52M +$3.17M +20,864 +6%
CC
15
Casdin Capital
New York
$50.4M
PC
16
Polar Capital
United Kingdom
$50M -$23.5M -154,529 -30%
Northern Trust
17
Northern Trust
Illinois
$49.5M -$334K -2,200 -0.6%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$46.3M +$2.34M +15,413 +5%
ACA
19
Avoro Capital Advisors
New York
$45.5M +$49.3M +325,000 New
TCM
20
TimesSquare Capital Management
New York
$42.8M +$5.29M +34,865 +13%
Ameriprise
21
Ameriprise
Minnesota
$42.6M +$12.2M +80,439 +36%
Victory Capital Management
22
Victory Capital Management
Texas
$39.8M -$9.98M -65,740 -19%
EAM
23
Eventide Asset Management
Massachusetts
$38.4M +$6.83M +45,000 +20%
CTA
24
Carillon Tower Advisers
Florida
$35.9M
DCM
25
Driehaus Capital Management
Illinois
$35.6M -$4.16M -27,425 -10%

LOXO Hedge Fund Activity: Q4 2018 in Review

232 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q4 2018, worth a combined $4.15B — down 19% from $5.13B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new LOXO positions and 31 closed out — a net gain of 5 holders — while 77 added to existing stakes and 85 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $72.3M. The largest seller was OrbiMed, exiting entirely with an estimated $56.4M sold.

  • 232 institutional investors held Loxo Oncology, Inc (LOXO) as of Q4 2018, up from 228 in Q3 2018.
  • Funds reported $4.15B of Loxo Oncology, Inc stock for Q4 2018, down 19% quarter-over-quarter.
  • 36 funds opened new Loxo Oncology, Inc positions in Q4 2018 and 31 closed out, a net change of +5 holders.
  • The largest Loxo Oncology, Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $72.3M added.
  • The largest Loxo Oncology, Inc seller in Q4 2018 was OrbiMed, an estimated $56.4M sold.

Based on aggregated 13F filings for Q4 2018.